Generic Lipitor Era Dawns With Watson’s Launch, Followed By Ranbaxy’s Last-minute Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva will share in Ranbaxy’s profits during its exclusivity period, as FDA announces approval of Ranbaxy’s first-filed ANDA more than 14 hours after Watson discloses that it began shipping its atorvastatin “authorized generic”.